ESMA published a four-part package under the Prospectus Regulation on 9 September 2026, aligning disclosure guidance, Q&As and technical standards with the changes introduced by the Listing Act. The package consists of a Consultation Paper on updated disclosure Guidelines (ESMA32-753890202-3085), revised Q&As, a Final Report on Guidelines for supplements that introduce new securities to a base prospectus (ESMA32-753890202-3034), and a Final Report on regulatory technical standards for key financial information in prospectus summaries (ESMA32-753890202-3065). All four documents carry the same 9 September 2026 date.

The authority frames the package as serving two purposes: promoting supervisory convergence and contributing to its simplification and burden-reduction agenda. For issuers and their advisers, the practical effect is a reworked disclosure rulebook — some guidance trimmed, some clarified, some new in application.

Consultation on disclosure Guidelines

The Consultation Paper seeks stakeholder feedback on updates intended to help issuers and their advisers better understand expected disclosure under the revised Prospectus Regulation. ESMA states the updates also simplify existing guidance by reducing the parts that are no longer necessary.

The deadline for responses is 9 November 2026. ESMA expects to publish the Final Report and updated Guidelines in Q2 2027. That timeline gives capital markets desks roughly two months to file comments and issuers with pending deals a known window before the guidance firms up.

Q&As

The revised Q&As adjust legal references to reflect the amended Prospectus Regulation, introduce further clarifications where needed, and remove obsolete content. To help stakeholders track the changes, ESMA has prepared a separate overview document explaining the key changes and the reasons behind them. Issuers and counsel relying on the previous Q&A set should treat the overview as the diff: it identifies what was renumbered, what was clarified and what was dropped.

Guidelines on product supplements

The Guidelines on product supplements — finalized, not proposed — establish a common approach for assessing whether a supplement introduces new securities to a base prospectus. ESMA says they provide national competent authorities with a methodological and easy-to-apply framework and give market participants greater certainty when submitting supplements.

The application date is tied to translation: the Guidelines take effect when translations into all official EU languages become available. No fixed date is given, so the operative trigger remains procedural rather than calendrical.

RTS on key financial information

The Final Report on RTS updates the requirements for financial information in prospectus summaries following the Listing Act reforms. ESMA states the standards align summary disclosure requirements with the revised disclosure framework and support more proportionate information requirements.

The RTS are not yet law. ESMA has submitted the Final Report to the European Commission, which must decide whether to adopt the standards updating Commission Delegated Regulation 2019/979. Until the Commission acts, the existing delegated regulation remains the binding text.

What is mandated versus what is proposed

The package splits into three categories by status. The Guidelines on product supplements are final and will apply upon translation. The RTS are final at ESMA level but await Commission adoption. The disclosure Guidelines remain under consultation until 9 November 2026, with the final version expected in Q2 2027. The Q&As, which ESMA publishes as clarifications rather than binding rules, took effect with the package release.

For ECM desks and issuers, the workload implications are concrete: comment letters on the disclosure Guidelines due within eight weeks, document templates and summary drafting practices to be revisited once the RTS are adopted, and supplement-submission processes to be checked against the new product-supplement framework once translations land.

ESMA's next milestone is the 9 November consultation deadline, followed by the Final Report and updated disclosure Guidelines in Q2 2027 and a Commission decision on the RTS in the interim.